A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.

PHASE1CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

May 13, 2016

Primary Completion Date

August 1, 2016

Study Completion Date

August 10, 2016

Conditions

Motion Sickness

Interventions

DRUG

Reformulated scopolamine patch

Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours

DRUG

Marketed scopolamine patch

Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.

Trial Locations (1)

GSK Investigational Site, Mont Royal, QC